Open Access

Metformin inhibits EV71‑induced pyroptosis by upregulating DEP domain‑containing mTOR‑interacting protein

  • Authors:
    • Xiaoyan Zhang
    • Chenxi Sun
    • Jinfang Hao
    • Li Cao
    • Xinyan Zhang
    • Jianping Du
    • Qian Han
  • View Affiliations

  • Published online on: June 29, 2023     https://doi.org/10.3892/etm.2023.12087
  • Article Number: 388
  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Enterovirus 71 (EV71) infection is one of the main causes of severe hand, foot and mouth disease (HFMD), which is usually accompanied by a marked inflammatory response. The excessive inflammatory response has been implicated to serve an important role in EV71‑caused HFMD. Pyroptosis is a type of inflammatory programmed cell death. Therefore, a novel treatment strategy against EV71 infection could aim to alleviate the inflammatory response through inhibition of EV71‑induced pyroptosis. The present study revealed that metformin had this therapeutic potential. A cell model of EV71 infection was established, cell viability was measured by CCK8 assay, cell damage was measured by LDH release kit, and the dead and dying cells were excluded by propidium iodide staining. The intracellular levels of DEP domain‑containing mTOR interacting protein (DEPTOR) and pyroptosis‑associated molecules were measured by western blot analysis, the NLRP3 expression was assessed by immunofluorescence labeling, and virus titers in cell culture supernatants were determined by a cell culture infectious dose 50 assay. The results demonstrated that EV71 infection could induce pyroptosis in a time‑ and dose‑dependent manner, and metformin could inhibit EV71‑induced pyroptosis. The mechanism of metformin inhibiting EV71‑induced pyroptosis was explored next. Subsequent experiments indicated that metformin could increase the levels of DEPTOR, which were decreased by EV71. Finally, overexpression of DEPTOR in cells could reduce EV71‑induced pyroptosis. Overall, the present study demonstrated that metformin could exert a novel pharmacodynamic anti‑pyroptosis effect in the treatment of EV71 infection by upregulating DEPTOR expression.

Introduction

Enterovirus 71 (EV71) belongs to the small ribonucleovirus family of the enterovirus genus, and is a non-envelope single-stranded RNA virus (1). Patients who are <6 years old with EV71 infection may suffer from brain stem encephalitis, neurogenic pulmonary edema, cardiac arrest and other fatal clinical symptoms, including death (2,3).

Previous studies have demonstrated that viral infections, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (4), influenza virus (5), hepatitis B virus (6) and West Nile virus (7), can induce pyroptosis, and our previous study has also indicated that EV71 infection could induce pyroptosis (8). Pyroptosis is a type of inflammatory programmed cell death. NLR family, pyrin domain-containing 3 (NLRP3) activation triggers NLRP3-inflammasome assembly, which results in pyroptosis initiation when viral infections occur. Caspase-1 is a downstream molecule of the inflammasome and activated caspase-1 initiates pyroptosis by cleaving gasdermin D (GSDMD). Activated caspase-1 also cleaves Pro-IL-1β into mature IL-1β. When pyroptosis occurs, the cleaved GSDMD forms a pore channel on the cell surface, which causes membrane rupture, cell death and release of the inflammatory cytokines IL-1β and IL-18. Therefore, IL-1β, which can induce the inflammatory reaction, is a sensitive marker of the activation of GSDMD (9-14).

It has been demonstrated that excessive inflammatory activation is one of the main causes of severe hand, foot and mouth disease (HFMD) (2,3). We hypothesized that the suppression of virus-induced cytotoxicity and pyroptosis with drugs can be a novel therapeutic strategy for EV71 infection. At present, certain researchers have tried to explore potential inhibitors to reduce the formation of GSDMD pore channels; for example, combination of dimethyl fumarate and cysteine residues limits the oligomerization of GSDMD in cells (15). In addition, the inhibition of diabetes-induced pyroptosis by inhibiting the thioredoxin interacting protein (TXNIP)/NLRP3 signaling pathway has been observed (16). In another study, paeoniflorin has been used to inhibit the activation of caspase-11, thereby aiming to inhibit the activation of the inflammatory caspase cascade to suppress inflammation (17).

Metformin was originally extracted from goat beans to treat diabetes (18). It has been demonstrated that metformin reduces liver glucose generation via the AMP-activated protein kinase (AMPK) signaling pathway (19). A previous study has revealed that metformin inhibits the production of IL-1β by macrophages (20), and that it interferes with the AMPK signaling pathway to suppress inflammation (21). Metformin has also been revealed to inhibit NLRP3(22). Another study has demonstrated that metformin inhibits cardiac muscle cell pyroptosis by inhibiting the TXNIP-NLRP3-GSDMD signaling pathway (23).

A recent study has indicated that metformin treatment can lower the mortality rate of diabetic patients infected with SARS-CoV-2(24). At present, to the best of our knowledge, there is no report on the effect of metformin treatment against EV71 infection or the effect of metformin on EV71-induced pyroptosis.

Previous studies suggest that metformin can increase DEP domain-containing mTOR-interacting protein (DEPTOR) levels in hepatoma cells, ureteral epithelial cells and rats with unilateral ureteral obstruction (25,26). DEPTOR is a component of the mTOR complex (mTORC)1 and mTORC2 and binds to mTOR to suppress its kinase activity (27). A study has demonstrated that DEPTOR serves an important role in immune regulation and that DEPTOR is higher in T cells before inflammatory activation (28). Zhai et al (29) revealed that DEPTOR deficiency in T cells is associated with NLRP3-activated IL-1β release. Another study has revealed that decreased DEPTOR levels induce the release of a large number of chemokines in endothelial cells, such as chemokine (C-X-Cmotif) ligand 9 (CXCL9), CXCL10, CXCL11, CX3CL1, chemokine (C-C motif) ligand 5 (CCL5) and CCL20(30). It has been revealed that DEPTOR is also regulated by the nuclear receptors of steroids, which can increase the levels of DEPTOR mRNA in cells (31). An androgen receptor repressor, prochloramide, is used in clinical treatment to control SARS-CoV-2 infection (32). It has been demonstrated that DEPTOR is regulated by the androgen receptor, which serves a negative role in the regulation of DEPTOR mRNA levels (33). Therefore the present study investigated whether EV71 could induce a change in the DEPTOR protein levels and what consequences this had on EV71-induced pyroptosis. In addition, in terms of inhibiting EV71-induced pyroptosis, the present study aimed to find a commercial drug that may be used in the treatment of EV71 infection and investigate its anti-pyroptosis mechanism.

Materials and methods

Reagents and antibodies

DMEM (cat. no. PYG0073), penicillin and streptomycin (cat. no. PYG0016), trypsin, BCA protein detection kit (cat. no. AR0146), ECL western blot detection kit (cat. no. AR1172), SDS-PAGE loading buffer (5X) (cat. no. AR1112-10), horseradish peroxidase-conjugated goat anti-rabbit IgG (H+L) (cat. no. BA1054) and GSDMD antibody (cat. no. A02842) were purchased from Boster Biological Technology. Cell Counting Kit (CCK-8) (cat. no. 40203ES76) was purchased from Yeasen Biotechnology (Shanghai) Co., Ltd.. Bovine serum albumin (cat. no. abs9157) was purchased from Absin Bioscience Inc., Fetal bovine serum (cat. no. 04-001-1A) were purchased from Biological Industries, metformin (cat. no. IM0140) were obtained from Beijing Solarbio Science & Technology Co., Ltd. DAPI (cat. no. C1002), Lipofectamine 8000 (cat. no. C0533-0.5ml), propidium iodide (PI; cat. no. ST511) and Alexa Fluor 488 goat anti-rabbit IgG antibody (cat. no. A0423) were purchased from Beyotime Biotechnology Company. The caspase-1 antibody (cat. no. A0964) and caspase 1 p20 (cat. no. A23429) were purchased from ABclonal Biotech Co., Ltd. The lactate dehydrogenase (LDH) detection kit (cat. no. WLA072a) and Pro-IL-1β (cat. no. WL02257) and NLRP3 (cat. no. WL02635) antibodies were purchased from Wanleibio Co., Ltd. The GAPDH (cat. no. BS65656) antibody was obtained from Bioworld Technology, Inc. The β-actin (cat. no. AB0061) antibody was purchased from Shanghai Abways Biotechnology Co., Ltd. The DEPTOR/DEPDC6 (D9F5) antibody (cat. no. #11816) was purchased from Cell Signaling Technology, Inc. pcDNA 3.1 and pcDNA 3.1-DEPTOR were purchased from Shanghai GenePharma Co., Ltd.

Cells and virus

GES-1 human normal gastric epithelial cells were purchased from Boster Biological Technology and RD human rhabdomyosarcoma cells were purchased from the National Collection of Authenticated Cell Cutures, and cultured in DMEM containing 10% fetal bovine serum and 1% penicillin and streptomycin in an incubator with 5% CO2 at 37˚C. EV71 was obtained from Professor Zhendong Zhao (Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College). GES-1 cells were infected with EV71 at various multiplicity of infections (MOIs) of 1, 2, 3, 4 or 5 for different times (12, 18 or 24 h) at 37˚C, and cells cultured in full culture medium without EV71 were used as the mock group (mock infection).

Cell culture infectious dose 50 (CCID 50) assay

RD cells (1x104/well) were seeded into 96-well plates and cultured in an incubator at 37˚C with 5% CO2 for 12 h. Subsequently, RD cells were infected with EV71 that was serially diluted from 1x101 to 1x1011 times, and cells in a total of eight wells per 96-well plate were infected with EV71 at the same dilution and cultured at 37˚C. The 96-well plates were observed once per day for 5 days. The wells with ~50% cytopathic effect of RD cells were observed under a microscope and recorded, and the CCID 50 results were calculated using the Reed-Münch method (34).

Measurement of LDH release

GES-1 cells were infected with EV71 at various MOIs of 1, 2, 3, 4 or 5 or infected with EV71 at MOI 5 and treated with metformin (1, 3 or 5 µM) for 24 h and then the cell supernatant was collected at 400 x g for 5 min at 4˚C. The LDH release of the cell supernatant was measured using an LDH detection kit. LDH activity (%) was calculated as follows: (LDHtreatment-LDHcontrol)/(LDHmax-LDHcontrol) x100.

Western blotting

GES-1 cells from different groups were collected in 1.5-ml centrifuge tubes and lysed with 60 µl RIPA lysis buffer (Beyotime Institute of Biotechnology). The total protein concentration was measured using a BCA kit. A total of 30 µg total extracted protein from each group was separated by 12% SDS-PAGE and then transferred to a nitrocellulose (NC) membrane. The NC membrane was blocked with 5% skimmed milk for 2 h at room temperature and then incubated with NLRP3 (1:1,000), GSDMD (1:1,000), caspase-1 (1:1,000), caspase-1 P20 (1:1,000), Pro-IL-1β (1:5,000), DEPTOR (1:1,000), GAPDH (1:5,000) and β-actin (1:5,000) antibodies overnight at 4˚C. Subsequently, the NC membrane was washed three times with TBST (0.1% Tween) and incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG secondary antibody (1:5,000) at room temperature for 2 h. Finally, immunoblots were incubated with an ECL chromogenic kit and observed using a ChemiDoc™ MP Imaging System (Bio-Rad Laboratories, Inc.). ImageJ software (version 6.0; National Institutes of Health) was used for densitometry.

Cell Counting Kit-8 (CCK-8) assay

GES-1 cells seeded onto 96-well plates were infected with EV71 at MOI 1, 2, 3, 4, or 5 or infected with EV71 at MOI 5 and treated with metformin (1, 3 or 5 µM) for 24 h at 37˚C with 5% CO2. At 2 h before the end of the culture, 20 µl CCK-8 reagent was added to the 96-well plates. Subsequently, the absorption of each sample was detected at 450 nm using a microplate reader (BioTek Instruments, Inc.). The cell viability was calculated using the following formula: Cell viability (%)=(Absorbancetreatment-Absorbanceblank)/(Absorbancecontrol-Absorbanceblank) x100%.

Immunofluorescence staining

GES-1 cells were seeded into 24-well plates (1x105 cells/well). When the EV71 infected-GES-1 cell density reached 60-70%, GES-1 cells were fixed with 4% paraformaldehyde at 4˚C for 20 min. Subsequently, the cells were permeated with 0.5% Triton X-100 at room temperature for 15 min and blocked with 5% bovine serum albumin at room temperature for 1 h. Then the cells were incubated with the NLRP3 antibody (1:200) at 4˚C overnight, followed by incubation with Alexa Fluor 488 goat anti-rabbit IgG (1:200) at room temperature for 1 h, and then protected from light and stained with 1 µg/ml DAPI solution in PBS for 5 min at room temperature. The cells were again protected from light and washed three times with PBS after each staining step. All images were observed under an inverted fluorescence microscope (x200 magnification2; Nikon Corporation).

PI staining

GES-1 cells in the logarithmic phase were seeded into 24-well plates (1.2x105/well) for 12 h and then treated with EV71, metformin (5 µM) or EV71 and metformin (5 µM) for 24 h at 37˚C. When the density of the treated cells reached ~80%, GES-1 cells were stained with 4 µM PI for 30 min at 37˚C. The images were captured using an inverted fluorescence microscope (magnification, x200; Nikon Corporation).

DNA transfection

GES-1 cells were plated into 6-well plates (50x104/well) for 12 h. Subsequently, 2.5 µg pcDNA 3.1 (negative control with empty vector) or pcDNA 3.1-DEPTOR and 5 µl Lipofectamine 8000 were added to 125 µl fresh DMEM (without bovine serum and antibiotics) and gently mixed. Then, the mixture was added to the 6-well plate. Cells were cultured at 37˚C, and subsequent experiments were carried out 48 h later.

Statistical analysis

GraphPad Prism 8 software (GraphPad Software; Dotmatics) was used for statistical tests. All experiments were independently repeated three times and data are presented as the mean ± SD. Multiple groups were analyzed through one-way ANOVA followed by Tukey's post hoc test. P<0.05 was considered to indicate a statistically significant difference.

Results

EV71 infection causes cell damage and reduces cell viability

GES-1 cells were treated with EV71 at the different MOIs (0, 1, 2, 3, 4 and 5) for 24 h. The cell viability of each group was detected using a CCK-8 assay (Fig. 1A). Subsequently, GES-1 cells were treated with EV71 at a MOI of 1, 3 and 5 for 24 h, and the cell damage level was measured using an LDH release assay (Fig. 1B). The results demonstrated that EV71 decreased cell viability and increased cell damage in a dose-dependent manner.

EV71 infection induces pyroptosis

The present study further examined whether pyroptosis is involved in EV71-induced cell damage. GES-1 cells were infected with EV71 at different MOIs (0, 1, 2, 3, 4 and 5) for 24 h. The protein levels of NLRP3, GSDMD, caspase-1 and Pro-IL-1β in cells were detected by western blotting. The results demonstrated that EV71 increased the levels of NLRP3, and decreased the levels of GSDMD, caspase-1 and Pro-IL-1β in a dose-dependent manner (Fig. 2A-C). Subsequently, GES-1 cells were infected with EV71 at a MOI of 5 for 12, 18 and 24 h. Compared to those of the mock group, the protein levels of GSDMD, and Pro-IL-1β were reduced in a time-independent manner, and caspase-1 was decreased significantly at 24 h (Fig. 2D and E). GES-1 cells were infected with EV71 at a MOI of 5 for 24 h, and the NLRP3 levels were examined using immunofluorescence staining. The results indicated that intracellular NLRP3 was upregulated and showed intracellular aggregation (Fig. 2F). These suggested that EV71 infection could induce cell pyroptosis.

Metformin reverses EV71-induced cytotoxicity and cell viability inhibition

The present study evaluated whether metformin was able to affect the viability of EV71-infected cells and reverse EV71-induced cytotoxicity. Shifts in cell viability and cell damage were detected using CCK-8 and LDH release assays. The cells were treated with EV71 (MOI=5) alone or combined with metformin at different concentrations (1, 3 and 5 µM) for 24 h. The cell viability was increased and cell damage was inhibited by 5 µM metformin treatment in EV71-infected cells compared with cells infected with EV71 only (Fig. 3A and B). Next, The GES-1 cells were stained with PI (red fluorescence), which was used to stain the dead and dying cells. EV71-treated cells exhibited cell injury and the number of GES-1 cells were decreased compared with that in the uninfected group, while treatment with metformin reversed the EV71-induced cell damage (Fig. 3C).

Metformin inhibits EV71-induced pyroptosis in GES-1 cells

In order to define whether metformin against EV71 induced cell pyroptosis, GES-1 cells were treated with EV71 and 2 µM metformin. Metformin upregulated Pro-IL-1β and downregulated caspase-1 P20 in EV71-infected cells compared with the EV71 infected group (P<0.01; Fig. 4A and B). EV71-infected GES-1 cells were treated with different concentrations (0, 1, 2, 3, 4 and 5 µM) of metformin for 24 h. The results revealed that NLRP3 and caspase-1 P20 were downregulated, and GSDMD, caspase-1 and Pro-IL-1β were upregulated (P<0.01; Fig. 4C-F) compared with the EV71 group. This indicated that metformin exerted substantial inhibitory effects on EV71-induced pyroptosis.

Metformin upregulates DEPTOR protein expression in GES-1 cells

GES-1 cells were infected with EV71 at various MOIs (0, 1, 2, 3, 4 and 5) for 24 h, and the results indicated that the protein levels of DEPTOR were decreased in a dose-dependent manner in EV71-infected GES-1 cells (P<0.01; Fig. 5A). Subsequently, GES-1 cells were infected with EV71 (MOI=5) at varying times (12, 18 and 24 h), and western blot analysis revealed the degradation of DEPTOR in a time-dependent manner compared with the mock group at the same time (P<0.01; Fig. 5B). Next, GES-1 cells were incubated with varying concentrations (0, 1, 2, 3, 4 and 5 µM) of metformin for 24 h, and the results indicated that metformin increased DEPTOR levels in a dose-dependent manner (P<0.01; Fig. 5C). Finally, DEPTOR protein levels were upregulated in EV71-infected and metformin-treated (0, 1, 2, 3, 4 and 5 µM) GES-1 cells compared with EV71-infected alone GES-1 cells (P<0.01; Fig. 5D).

The results demonstrated that metformin could reverse the downregulating effect of EV71 on DEPTOR. The alterations of DEPTOR were accompanied by changes in pyroptosis that were regulated by EV71 or metformin, as aforementioned. These findings suggested a potential association between pyroptosis and DEPTOR expression.

Overexpression of DEPTOR inhibits EV71-induced pyroptosis

EV71 infection induced pyroptosis and the degradation of DEPTOR, which were reversed by metformin treatment. Next, the present study aimed to further investigate the association between pyroptosis and DEPTOR. pcDNA 3.1 and pcDNA 3.1-DEPTOR were transfected into GES-1 cells, which were then infected with EV71. The changes of pyroptosis-related proteins were observed. The results showed that after EV71 infection, compared with that of the empty vector expression group, the level of GSDMD and DEPTOR was increased (P<0.01; Fig. 6A), caspase-1 level was increased (P<0.01; Fig. 6B), caspase-1 P20 level was decreased (P<0.05; Fig. 6B), the expression of NLRP3 was reduced (P<0.01; Fig. 6C) and the level of Pro-IL-1β was increased (P<0.01; Fig. 6D) in the DEPTOR overexpression group. The results demonstrated that DEPTOR overexpression led to inhibition of pyroptosis and indicated that metformin inhibited EV71-induced pyroptosis via upregulating DEPTOR.

Discussion

EV71 infection causes HFMD in infants and children, particularly severe infections with pulmonary edema and neurological complications, which pose a serious threat to the life and health of children. There is no specific drug to control EV71 infection at present, thus it is important to investigate anti-infection mechanisms and find effective antiviral drugs (35). Viral infection induces pyroptosis and causes an inflammation response. We hypothesized that targeting the virus-induced pyroptosis and its initiated inflammation can be an innovative strategy for antiviral treatment. In the present study, the inhibitory effect of metformin on EV71-induced pyroptosis and the upregulating effect of metformin on DEPTOR levels were revealed. It was demonstrated that DEPTOR was involved in the inhibitory process of EV71-induced pyroptosis, which provided a reference for discovering effective anti-EV71 infection drugs.

The present study first confirmed that EV71 infection increased cell damage and decreased cell viability, and that 5 µM metformin treatment reversed this cytotoxicity. This finding suggests that metformin may play a protective role in EV71 infections. EV71 infected GES-1 cells exhibited pyroptosis, accompanied by caspase-1 activation, GSDMD increase and IL-1β maturation. This finding is consistent with the work of Yogarajah et al (36) showing that EV71 induced host cell pyroptosis. Other studies have demonstrated that EV71 3C protease inhibits the activation of GSDMD (36-38). It is possible that the viral protease prolongs the proliferation stage of the virus in cells by inhibiting pyroptosis in the early stage of infection (39). However, a large number of aggregating progeny viruses eventually lead to the occurrence of pyroptosis in the later stage of infection, which causes the release of mature viruses and inflammatory cytokines, increases infection and pathogenesis, and causes further serious pathological damage to the body. This hypothesis is supported by the marked intracellular elevation of viral structure protein VP1 and the pyroptosis-related proteins NLRP3, GSDMD, Caspase-1 and Pro IL-1β 24 h after infection (40). The present study subsequently tried to find a marketed drug that could suppress pyroptosis to shorten its clinical trial period. It was revealed that metformin could inhibit EV71-induced cell damage and pyroptosis in a dose-dependent manner. This finding demonstrated the anti-pyroptosis effect of metformin in a novel model, which further supplemented the pharmacological effects of metformin.

The anti-pyroptosis mechanism of metformin was investigated further, and it was revealed that metformin could regulate DEPTOR. DEPTOR, as a metabolic pathway inhibitor protein, is upregulated by corticosteroids (31). It was explored whether the levels of DEPTOR changed in the EV71-infection model and whether metformin could regulate DEPTOR. The results demonstrated that EV71 infection reduced, while metformin increased the cellular levels of DEPTOR which is consistent with the findings of Obara et al (25). In the present cell model of EV71 infection, metformin reversed EV71-induced DEPTOR reduction in a dose-dependent manner, suggesting that metformin may exert its effect by upregulating the expression levels of DEPTOR.

The present study subsequently aimed to determine whether DEPTOR is involved in the regulation of virus-induced pyroptosis. The effects of DEPTOR overexpression on NLRP3, Pro-IL-1β, caspase-1, caspase-1 P20 and GSDMD were detected. The results demonstrated that DEPTOR overexpression could suppress EV71-induced pyroptosis. Zhai et al (29) indicated that the reduced level of DEPTOR can activate NLRP3 and mature IL-1β in macrophages. DEPTOR knockdown experiments were conducted in metformin-treated cells in the present study with an aim to observe whether the effect of metformin on pyroptosis can be inhibited. However, knockdown experiments require prolonged cell cultivation that make the expression level of DEPTOR in cells too low to detect. This is a limitation of the present study and an aim in future research to improve upon. The present study demonstrated that metformin could inhibit EV71-induced pyroptosis by upregulating DEPTOR. However, the mechanism via which metformin upregulates DEPTOR and how DEPTOR regulates pyroptosis should be investigated in the future.

In future studies on this topic, the first consideration should be to further investigate the association between DEPTOR and the pyroptosis pathway. Peterson et al (41) revealed that overexpression of DEPTOR activates the mTORC2/AKT signaling pathway, leading to an increase in phosphorylation at the Ser-473 site of AKT. Zhao et al (42) revealed that activation of AKT inhibits NLRP3 degradation, thereby suppressing NLRP3 oligomerization and activation. Considering the relationship between AKT and mTORC2, it may be hypothesized that DEPTOR may affect AKT activity through mTORC2 to regulate NLRP3 oligomerization and inhibit pyroptosis.

In conclusion, the findings of the present study suggested that EV71 infection induced GES-1 cell pyroptosis, while metformin suppressed EV71-induced pyroptosis, alleviated cytotoxicity and the inflammatory response. The implicated mechanism may involve the upregulation of DEPTOR by metformin.

Acknowledgements

The authors would like to thank Professor Zhendong Zhao (Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China) for his gift of cell lines and virus.

Funding

Funding: The present study was supported by the National Natural Science Foundation of China (grant no. 81301426), the Provincial Natural Science Foundation of Shanxi (grant no. 201901D111329), the Mega Research and Development Projects of Lüliang (grant no. 2020SHFZ38), the Program of Fenyang College, Shanxi Medical University (grant no. 2020B01) and the Key Laboratory Platform Construction Projects of Lüliang (grant no. 2020ZDSYS17).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

XiaZ and CS conceived and designed the experiments. CS, XiaZ, JH, LC and XinZ performed the experiments. CS, JD, QH analyzed the data. XiaZ and CS wrote the manuscript. XiaZ and JH revised the manuscript. All authors have read and approved the final manuscript. XiaZ and CS confirm the authenticity of all the raw data.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1 

Huang SW, Kiang D, Smith DJ and Wang JR: Evolution of re-emergent virus and its impact on enterovirus 71 epidemics. Exp Biol Med (Maywood). 236:899–908. 2011.PubMed/NCBI View Article : Google Scholar

2 

Chen Y, Hu L, Xu F, Liu C and Li J: A case report of a teenager with severe hand, foot, and mouth disease with brainstem encephalitis caused by enterovirus 71. BMC Pediatr. 19(59)2019.PubMed/NCBI View Article : Google Scholar

3 

Xing J, Wang K, Wei H and Wei D: Pathologic and molecular studies of enterovirus 71 infection in a fatal case from a recent epidemic in China. Medicine (Baltimore). 97(e13447)2018.PubMed/NCBI View Article : Google Scholar

4 

Sun X, Liu Y, Huang Z, Xu W, Hu W, Yi L, Liu Z, Chan H, Zeng J, Liu X, et al: SARS-CoV-2 non-structural protein 6 triggers NLRP3-dependent pyroptosis by targeting ATP6AP1. Cell Death Differ. 29:1240–1254. 2022.PubMed/NCBI View Article : Google Scholar

5 

Allen IC, Scull MA, Moore CB, Holl EK, McElvania-TeKippe E, Taxman DJ, Guthrie EH, Pickles RJ and Ting JP: The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity. 30:556–565. 2009.PubMed/NCBI View Article : Google Scholar

6 

Xie WH, Ding J, Xie XX, Yang XH, Wu XF, Chen ZX, Guo QL, Gao WY, Wang XZ and Li D: Hepatitis B virus X protein promotes liver cell pyroptosis under oxidative stress through NLRP3 inflammasome activation. Inflamm Res. 69:683–696. 2020.PubMed/NCBI View Article : Google Scholar

7 

Ramos HJ, Lanteri MC, Blahnik G, Negash A, Suthar MS, Brassil MM, Sodhi K, Treuting PM, Busch MP, Norris PJ and Gale M Jr: IL-1β signaling promotes CNS-intrinsic immune control of West Nile virus infection. PLoS Pathog. 8(e1003039)2012.PubMed/NCBI View Article : Google Scholar

8 

Zhang X, Hao J, Sun C, Du J, Han Q and Li Q: Total astragalosides decrease apoptosis and pyroptosis by inhibiting enterovirus 71 replication in gastric epithelial cells. Exp Ther Med. 23(237)2022.PubMed/NCBI View Article : Google Scholar

9 

Kayagaki N, Stowe IB, Lee BL, O'Rourke K, Anderson K, Warming S, Cuellar T, Haley B, Roose-Girma M, Phung QT, et al: Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature. 526:666–671. 2015.PubMed/NCBI View Article : Google Scholar

10 

Fink SL and Cookson BT: Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages. Cell Microbiol. 8:1812–1825. 2006.PubMed/NCBI View Article : Google Scholar

11 

Kesavardhana S, Malireddi RKS and Kanneganti T: Caspases in cell death, inflammation, and gasdermin-induced pyroptosis. Annu Rev Immunol. 38:567–595. 2020.PubMed/NCBI View Article : Google Scholar

12 

Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, Zhuang Y, Cai T, Wang F and Shao F: Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 526:660–665. 2015.PubMed/NCBI View Article : Google Scholar

13 

He WT, Wan H, Hu L, Chen P, Wang X, Huang Z, Yang ZH, Zhong CQ and Han J: Gasdermin D is an executor of pyroptosis and required for interleukin-1β secretion: Gasdermin D is an executor of pyroptosis and required for interleukin-1beta secretion. Cell Res. 25:1285–1298. 2015.PubMed/NCBI View Article : Google Scholar

14 

Lamkanfi M and Dixit VM: Mechanisms and functions of inflammasomes. Cell. 157:1013–1022. 2014.PubMed/NCBI View Article : Google Scholar

15 

Humphries F, Shmuel-Galia L, Ketelut-Carneiro N, Li S, Wang B, Nemmara VV, Wilson R, Jiang Z, Khalighinejad F, Muneeruddin K, et al: Succination inactivates gasdermin D and blocks pyroptosis. Science. 369:1633–1637. 2020.PubMed/NCBI View Article : Google Scholar

16 

An X, Zhang Y, Cao Y, Chen J, Qin H and Yang L: Punicalagin protects diabetic nephropathy by inhibiting pyroptosis based on TXNIP/NLRP3 pathway. Nutrients. 12(1516)2020.PubMed/NCBI View Article : Google Scholar

17 

Tian DD, Wang M, Liu A, Gao MR, Qiu C, Yu W, Wang WJ, Zhang K, Yang L, Jia YY, et al: Antidepressant effect of paeoniflorin is through inhibiting pyroptosis CASP-11/GSDMD pathway. Mol Neurobiol. 58:761–776. 2021.PubMed/NCBI View Article : Google Scholar

18 

Bailey CJ: Metformin: Historical overview. Diabetologia. 60:1566–1576. 2017.PubMed/NCBI View Article : Google Scholar

19 

Agius L, Ford BE and Chachra SS: The metformin mechanism on gluconeogenesis and AMPK activation: The metabolite perspective. Int J Mol Sci. 21(3240)2020.PubMed/NCBI View Article : Google Scholar

20 

Qing L, Fu J, Wu P, Zhou Z, Yu F and Tang J: Metformin induces the M2 macrophage polarization to accelerate the wound healing via regulating AMPK/mTOR/NLRP3 inflammasome singling pathway. Am J Transl Res. 11:655–668. 2019.PubMed/NCBI

21 

Chen X, Li X, Zhang W, He J, Xu B, Lei B, Wang Z, Cates C, Rousselle T and Li J: Activation of AMPK inhibits inflammatory response during hypoxia and reoxygenation through modulating JNK-mediated NF-κB pathway. Metabolism. 83:256–270. 2018.PubMed/NCBI View Article : Google Scholar

22 

Yan J, Ding D, Feng G, Yang Y, Zhou Y, Ma L, Guo H, Lu Z and Jin Q: Metformin reduces chondrocyte pyroptosis in an osteoarthritis mouse model by inhibiting NLRP3 inflammasome activation. Exp Ther Med. 23(222)2022.PubMed/NCBI View Article : Google Scholar

23 

Jia Y, Cui R, Wang C, Feng Y, Li Z, Tong Y, Qu K, Liu C and Zhang J: Metformin protects against intestinal ischemia-reperfusion injury and cell pyroptosis via TXNIP-NLRP3-GSDMD pathway. Redox Biol. 32(101534)2020.PubMed/NCBI View Article : Google Scholar

24 

Samuel SM, Varghese E and Büsselberg D: Therapeutic potential of metformin in COVID-19: Reasoning for its protective role. Trends Microbiol. 29:894–907. 2021.PubMed/NCBI View Article : Google Scholar

25 

Obara A, Fujita Y, Abudukadier A, Fukushima T, Oguri Y, Ogura M, Harashima S, Hosokawa M and Inagaki N: DEPTOR-related mTOR suppression is involved in metformin's anti-cancer action in human liver cancer cells. Biochem Biophys Res Commun. 460:1047–1052. 2015.PubMed/NCBI View Article : Google Scholar

26 

Wang Y, Wang Y, Li Y, Lu L, Peng Y, Zhang S and Xia A: Metformin attenuates renal interstitial fibrosis through upregulation of Deptor in unilateral ureteral obstruction in rats. Exp Ther Med. 20(1)2020.PubMed/NCBI View Article : Google Scholar

27 

Caron A, Briscoe DM, Richard D and Laplante M: DEPTOR at the nexus of cancer, metabolism, and immunity. Physiol Rev. 98:1765–1803. 2018.PubMed/NCBI View Article : Google Scholar

28 

Wedel J, Bruneau S, Liu K, Kong SW, Sage PT, Sabatini DM, Laplante M and Briscoe DM: DEPTOR modulates activation responses in CD4+ T cells and enhances immunoregulation following transplantation. Am J Transplant. 19:77–88. 2018.PubMed/NCBI View Article : Google Scholar

29 

Zhai Y, Lin P, Feng Z, Lu H, Han Q, Chen J, Zhang Y, He Q, Nan G, Luo X, et al: TNFAIP3-DEPTOR complex regulates inflammasome secretion through autophagy in ankylosing spondylitis monocytes. Autophagy. 14:1629–1643. 2018.PubMed/NCBI View Article : Google Scholar

30 

Bruneau S, Nakayama H, Woda CB, Flynn EA and Briscoe DM: DEPTOR regulates vascular endothelial cell activation and proinflammatory and angiogenic responses. Blood. 122:1833–1842. 2013.PubMed/NCBI View Article : Google Scholar

31 

Laplante M, Horvat S, Festuccia WT, Birsoy K, Prevorsek Z, Efeyan A and Sabatini DM: DEPTOR cell-autonomously promotes adipogenesis, and its expression is associated with obesity. Cell Metab. 16:202–212. 2012.PubMed/NCBI View Article : Google Scholar

32 

Cadegiani FA, McCoy J, Gustavo Wambier C, Vaño-Galván S, Shapiro J, Tosti A, Zimerman RA and Goren A: Proxalutamide significantly accelerates viral clearance and reduces time to clinical remission in patients with mild to moderate COVID-19: Results from a randomized, double-blinded, placebo-controlled trial. Cureus. 13(e13492)2021.PubMed/NCBI View Article : Google Scholar

33 

Kanno Y, Zhao S, Yamashita N, Yanai K, Nemoto K and Inouye Y: Androgen receptor functions as a negative transcriptional regulator of DEPTOR, mTOR inhibitor. J Toxicol Sci. 40:753–758. 2015.PubMed/NCBI View Article : Google Scholar

34 

Reed LJ and Muench H: A simple method for estimating fifty percent endpoints. Am J Hyg. 27:493–497. 1938.

35 

Nayak G, Bhuyan SK, Bhuyan R, Sahu A, Kar D and Kuanar A: Global emergence of Enterovirus 71: A systematic review. Beni Suef Univ J Basic Appl Sci. 11(78)2022.PubMed/NCBI View Article : Google Scholar

36 

Yogarajah T, Ong KC, Perera D and Wong KT: AIM2 inflammasome-mediated pyroptosis in enterovirus A71-infected neuronal cells restricts viral replication. Sci Rep. 7(5845)2017.PubMed/NCBI View Article : Google Scholar

37 

Bai J, Chen X, Liu Q, Zhou X and Long JE: Characteristics of enterovirus 71-induced cell death and genome scanning to identify viral genes involved in virus-induced cell apoptosis. Virus Res. 265:104–114. 2019.PubMed/NCBI View Article : Google Scholar

38 

Wang H, Lei X, Xiao X, Yang C, Lu W, Huang Z, Leng Q, Jin Q, He B, Meng G and Wang J: Reciprocal regulation between enterovirus 71 and the NLRP3 inflammasome. Cell Rep. 12:42–48. 2015.PubMed/NCBI View Article : Google Scholar

39 

Chen H, Ning X and Jiang Z: Caspases control antiviral innate immunity. Cell Mol Immunol. 14:736–747. 2017.PubMed/NCBI View Article : Google Scholar

40 

Wang SM, Lei HY and Liu CC: Cytokine immunopathogenesis of enterovirus 71 brain stem encephalitis. Clin Dev Immunol. 2012(876241)2012.PubMed/NCBI View Article : Google Scholar

41 

Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, Gray NS and Sabatini DM: DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell. 137:873–886. 2009.PubMed/NCBI View Article : Google Scholar

42 

Zhao W, Shi CS, Harrison K, Hwang IY, Nabar NR, Wang M and Kehrl JH: AKT regulates NLRP3 inflammasome activation by phosphorylating NLRP3 serine 5. J Immunol. 205:2255–2264. 2020.PubMed/NCBI View Article : Google Scholar

Related Articles

Journal Cover

August-2023
Volume 26 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang X, Sun C, Hao J, Cao L, Zhang X, Du J and Han Q: Metformin inhibits EV71‑induced pyroptosis by upregulating DEP domain‑containing mTOR‑interacting protein. Exp Ther Med 26: 388, 2023
APA
Zhang, X., Sun, C., Hao, J., Cao, L., Zhang, X., Du, J., & Han, Q. (2023). Metformin inhibits EV71‑induced pyroptosis by upregulating DEP domain‑containing mTOR‑interacting protein. Experimental and Therapeutic Medicine, 26, 388. https://doi.org/10.3892/etm.2023.12087
MLA
Zhang, X., Sun, C., Hao, J., Cao, L., Zhang, X., Du, J., Han, Q."Metformin inhibits EV71‑induced pyroptosis by upregulating DEP domain‑containing mTOR‑interacting protein". Experimental and Therapeutic Medicine 26.2 (2023): 388.
Chicago
Zhang, X., Sun, C., Hao, J., Cao, L., Zhang, X., Du, J., Han, Q."Metformin inhibits EV71‑induced pyroptosis by upregulating DEP domain‑containing mTOR‑interacting protein". Experimental and Therapeutic Medicine 26, no. 2 (2023): 388. https://doi.org/10.3892/etm.2023.12087